EUCTR2010-023111-34-FR进行中（未招募）1 期
A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed and dated written informed consent obtained from the patient in accordance with the local regulations.
- •2.Diagnosis of moderate to severe SMD, with at least one pathogenic mutation in the ABCA4 gene on each chromosome, previously confirmed by direct sequencing and co-segregation analysis within the patient’s family.
- •3.Women of childbearing potential must have a negative pregnancy test at screening and at baseline, and agreement to using an effective form of contraception such as the contraceptive pill or intra uterine device, or be surgically sterile or postmenopausal, with the last menstrual period being over two years ago. Partners of study patients must agree to use barrier contraception for at least three months after StarGen administration.
- •4.Males must agree with their partner to use two forms of contraception, including one barrier method for at least three months following StarGen administration if their partner is of child-bearing potential, or must be surgically sterile.
- •5.Affiliated with the French social security healthcare system (French patients only).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pre-existing eye conditions that would preclude the planned surgery or interfere with the interpretation of study endpoints: glaucoma or other primary optic neuropathy that has resulted in significant visual field loss, corneal or significant lens opacities, active uveitis, retinopathy and maculopathy (other than that from Stargardt disease) that in the opinion of the investigator is causing significant visual loss, myopia greater than eight diopters spherical equivalent.
- •2.Cataract surgery with intraocular lens implantation within 6 months of enrolment.
- •3.Aphakia or prior vitrectomy in the study eye.
- •4.Concomitant systemic diseases including those in which the disease itself, or the treatment for the disease, can alter ocular function. For instance malignancies whose treatment could affect central nervous system function, diabetes, juvenile rheumatoid arthritis or sickle cell disease.
- •5.Any intraocular surgery or laser in either eye within 6 months of Day 0.
- •6.Any contraindication to pupil dilation in either eye.
- •7.Any known allergy to any component of the delivery vehicle or diagnostic agents used during the study (e.g., fluorescein, dilation drops), or medications planned for use in the peri-operative period, particularly topical, injected or systemic cortico-steroids.
- •8.Any injectable intravitreal treatment to the treated eye or intravitreal device in the treated eye within 6 months prior to screening.
- •9.Any periocular injections of corticosteroids to the treated eye within 4 months prior to screening.
- •10.Clinically significant laboratory test abnormalities, including full blood count, chemistry panel, liver function tests, electrocardiogram and chest X rays, that in the opinion of the principal investigator, would make the patient unsuitable for participation in the study.
- •11.Significant intercurrent illness or infection during the 28 days prior to enrolment.
- •12.Pre-menopausal or non-surgically sterile women who are unwilling to use an effective form of contraception such as the contraceptive pill or intrauterine device.
- •13.Men or women who do not agree to use contraception as specified in the inclusion criteria.
- •14.Alcohol or other substance abuse.
- •15.Contraindications to use of anaesthesia (local or general, as appropriate).
- •16.Concurrent anti-retroviral therapy that would inactivate the investigational agent.
- •17.History of any investigational agent within 28 days prior to StarGen administration.
- •18.Participation in a prior ocular gene transfer therapy study.
- •19.Enrolment in any other clinical treatment study, for any condition, including those relating to SMD, throughout the duration of the StarGen study.
- •20.Current or anticipated treatment with anticoagulant therapy or the use of anticoagulation therapy within the four weeks prior to surgery.
- •21.Past medical history of HIV or Hepatitis A, B or C.
- •22.Inability to comply with the demands of the study.
研究者
相似试验
撤回
不适用
A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients with Stargardt's Macular Degeneration.Fundus flavimaculatusNL-OMON43680Sanofi-aventis6
进行中（未招募）
不适用
A Phase I/IIa Study of SAR422459 in Patients With Stargardt Macular DegeneratioStargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease.MedDRA version: 18.1Level: PTClassification code 10062766Term: Stargardt's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-023111-34-NLsanofi-aventis recherche et développement46
进行中（未招募）
1 期
Study of SAR421869 in Patients With Retinitis Pigmentosa associated with Usher Syndrome Type 1BRetinitis Pigmentosa, associated with Ushers Syndrome Type 1B.MedDRA version: 20.0Level: PTClassification code 10038914Term: Retinitis pigmentosaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10063396Term: Usher's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-002574-31-FRsanofi-aventis recherche & développement9
进行中（未招募）
1 期
A Phase I/IIa Study of SAR422459 in Patients With Stargardt's Macular DegeneratioEUCTR2010-023111-34-ITSANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT27
尚未招募
1 期
A Phase 1 Study for patients with advanced solid tumors.CTRI/2011/12/002225Orchid Research Laboratories Ltd36